Kodiak Sciences (KOD) Convertible Debt (2017 - 2018)
Kodiak Sciences (KOD) reported Convertible Debt of $41.5 million for Q3 2018, up 318.06% quarter-over-quarter from $9.9 million in Q4 2017.
Kodiak Sciences (KOD) Convertible Debt (2017 - 2018) Analysis & Trends
Kodiak Sciences has reported Convertible Debt for 2 years, with the latest figure at $41.5 million in Q3 2018.
- For the quarter ending Q3 2018, Convertible Debt changed N/A year-over-year to $41.5 million; the trailing twelve-month figure through Sep 2018 stood at $41.5 million (changed N/A YoY), and the FY2017 full-year result was $9.9 million, changed N/A from the prior year.
- Convertible Debt for Q3 2018 stood at $41.5 million, up from $9.9 million in the prior quarter.
- The five-year high for Convertible Debt was $41.5 million in Q3 2018, with the low at $9.9 million in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Kodiak Sciences | 1.95 Bn | 1.95 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | 41.48 Mn |
| Dec 31, 2017 | 9.92 Mn |